

FILE 'HOME' ENTERED AT 15:50:51 ON 16 JUL 2003

=> fl medline caplus cancerlit
COST IN U.S. DOLLARS
TOTAL

FULL ESTIMATED COST ENTRY SESSION
0.21 0.21

FILE 'MEDLINE' ENTERED AT 15:31:07 ON 16 JUL 2003

FILE 'CAPLUS' ENTERED AT 15:31:07 ON 16 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN
CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL
SOCIETY (ACS)

FILE 'CANCERLIT' ENTERED AT 15:31:07 ON 16 JUL 2003

=> s hexadecylphosphocholine
L1 618 HEXADECYLPHOSPHOCHOLINE

=> s ll and gene therapy
L2 1 L1 AND GENE THERAPY

=> d

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003
ACS

AN 2001-923645 CAPLUS
DN 13648434

T1 Combination product intended for carrying out a
cytotoxic treatment, in
particular an antitumour treatment, in a mammal
IN Meyer, Olivier
PA Transgene S.A., Fr.
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

PATENT NO. KIND DATE APPLICATION
NO. DATE

PI WO 2001095946 A2 20011220 WO 2001-
IB1287 20010613

WO 2001095946 A3 20020906

W: AU, CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL,

PT, SE, TR

EP 1289568 A2 20030312 EP 2001-947745
20010613

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI,
LU, NL, SE, MC, PT,
IE, FI, CY, TR

US 2002025941 A1 20020228 US 2001-880038
20010614

PRAI FR 2000-7604 A 20000614

US 2000-246090P P 20001107

WO 2001-IB1287 W 20010613

OS MARPAT 13648434

=>
Connection closed by remote host

Welcome to STN International! Enter x.x

LOG(INID:asspta1633)ja

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR 7):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar
Schedule - N. America

NEWS 2 "Ask CAS" for self-help around the clock

NEWS 3 Feb 24 PCTGEN now available on STN

NEWS 4 Feb 24 TEMA now available on STN

NEWS 5 Feb 26 NTIS now allows simultaneous left and
right truncation

NEWS 6 Feb 26 PCTFULL now contains images

NEWS 7 Mar 04 SDI PACKAGE for monthly delivery
of multiple SDI results

NEWS 8 Mar 24 PATDPAFULL now available on STN

NEWS 9 Mar 24 Additional information for trade-named
substances without

structures available in REGISTRY

NEWS 10 Apr 11 Display formats in DGENE enhanced

NEWS 11 Apr 14 MEDLINE Reload

NEWS 12 Apr 17 Polymer searching in REGISTRY
enhanced

NEWS 13 Jun 13 Indexing from 1947 to 1956 added to
records in CA/CAPLUS

NEWS 14 Apr 21 New current-awareness alert (SDI)
frequency in

WPDIS/WPINDEX/WPIX

NEWS 15 Apr 28 DISCLOSURE now available on
STN

NEWS 16 May 05 Pharmacokinetic information and
systematic chemical names

added to PHAR

NEWS 17 May 15 MEDLINE file segment of
TOXCENTER reloaded

NEWS 18 May 15 Supporter information for
ENCOMPAT and ENCOMPLIT updated

NEWS 19 May 19 Simultaneous left and right truncation
added to WSCA

NEWS 20 May 19 RAPRA enhanced with new search
field, simultaneous left and

right truncation

NEWS 21 Jun 06 Simultaneous left and right truncation
added to CBNB

NEWS 22 Jun 06 PASCAL enhanced with additional
data

NEWS 23 Jun 20 2003 edition of the FSTA Thesaurus is
now available

NEWS 24 Jun 25 HSDB has been reloaded

NEWS EXPRESS April 4 CURRENT WINDOWS
VERSION IS V6.01a, CURRENT

MACINTOSH VERSION IS V6.0b(ENG) AND

V6.0b(JP).

AND CURRENT DISCOVER FILE IS DATED

01 APRIL 2003

NEWS HOURS STN Operating Hours Plus Help Desk
Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication

Network Access to STN

NEWS WWW CAS World Wide Web Site (general
information)

Enter NEWS followed by the item number or name to see
news on that

specific topic.

All use of STN is subject to the provisions of the STN
Customer

agreement. Please note that this agreement limits use to
scientific

research. Use for software development or design or
implementation

of commercial gateways or other similar uses is prohibited
and may

result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 15:52:21 ON 16 JUL 2003

=> fl medline caplus embase cancerlit biosis

'CANCERLIT' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a
list of files

that are available. If you have requested multiple files, you
can

specify a corrected file name or you can enter "IGNORE"

to continue

accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE) cancerlit

COST IN U.S. DOLLARS SINCE FILE

TOTAL

FULL ESTIMATED COST ENTRY SESSION
0.21 0.21

FILE 'MEDLINE' ENTERED AT 15:52:42 ON 16 JUL 2003

FILE 'CAPLUS' ENTERED AT 15:52:42 ON 16 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN

CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL

SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:52:42 ON 16 JUL 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights
reserved.

FILE 'CANCERLIT' ENTERED AT 15:52:42 ON 16 JUL 2003

FILE 'BIOSIS' ENTERED AT 15:52:42 ON 16 JUL 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS
INC.(R)

=> s hexadecylphosphocholine

L1 1105 HEXADECYLPHOSPHOCHOLINE

=> s ll and cytotox?

L2 219 L1 AND CYTOTOX?

=> dup rem l2

PROCESSING COMPLETED FOR L2

L3 80 DUP REM L2 (139 DUPLICATES
REMOVED)

=> s l3 and (treat? or therap?)

4 FILES SEARCHED...

L4 46 L3 AND (TREAT? OR THERAP?)

=> dup rem l4

PROCESSING COMPLETED FOR L4

L5 46 DUP REM L4 (0 DUPLICATES REMOVED)

=> d l5-22 u so

L5 ANSWER 15 OF 46 BIOSIS COPYRIGHT 2003
BIOLOGICAL ABSTRACTS INC.

T1 Physical properties and pharmacological activity in
vitro and in vivo of

optimised liposomes prepared from a new cancerostatic
alkylphospholipid.

SO Biochimica et Biophysica Acta, (Nov. 11, 1998) Vol.
1414, No. 1-2, pp.

238-248.

ISSN: 0006-3002.

L5 ANSWER 16 OF 46 CAPLUS COPYRIGHT 2003
ACS

T1 The effect of hexadecylphosphocholine on the
proliferation of

human keratinocytes in vitro and in vivo

SO Drugs of Today (1998), 34(Suppl. F), 97-105

CODEN: MDACAP; ISSN: 0025-7656

L5 ANSWER 17 OF 46 CAPLUS COPYRIGHT 2003
ACS

T1 Morphological changes and cytokine gene expression
in tumor xenografts

following treatment with the alkylphosphocholines
hexadecylphosphocholine and perfluorine

SO Drugs of Today (1998), 34(Suppl. F), 15-26

CODEN: MDACAP; ISSN: 0025-7656

L5 ANSWER 18 OF 46 MEDLINE

T1 The antiproliferative effect of
hexadecylphosphocholine toward

HL60 cells is prevented by exogenous
lysophosphatidylcholine.

SO BIOCHIMICA ET BIOPHYSICA ACTA, (1998 Jan
5) 1389 (1) 1-12.

Journal code: 0217513. ISSN: 0006-3002.

L5 ANSWER 19 OF 46 CAPLUS COPYRIGHT 2003
ACS

T1 The influence of 1-beta-D-arabinofuranosylcytosine
on the metabolism of

phosphatidylcholine in human leukemic HL 60 and Raji
cells

SO Leukemia (1997), 11(12), 2079-2086

CODEN: LEUKED; ISSN: 0887-6924

L5 ANSWER 20 OF 46 CAPLUS COPYRIGHT 2003
ACS

T1 Synergistic cytotoxic effects of ether phospholipid
analogues and

ionizing radiation in human carcinoma cells

SO Radiotherapy and Oncology (1997), 43(3), 293-301

CODEN: RAONDT; ISSN: 0167-8140

L5 ANSWER 21 OF 46 MEDLINE

T1 Antiproliferation effects of hexadecylphosphocholine
on solid

tumour and leukaemia selectively in vitro.

SO DRUGS UNDER EXPERIMENTAL AND
CLINICAL RESEARCH, (1997) 23 (3-4) 97-102.

Journal code: 7802135. ISSN: 0378-6501.

L5 ANSWER 22 OF 46 CAPLUS COPYRIGHT 2003
ACS

T1 Morphological and immunological observations on the
effects of

hexadecylphosphocholine (HPC) in nude mice bearing
MT-1 breast

cancer xenografts

SO Anticancer Research (1997), 17(1A), 37-43

CODEN: ANTRD4; ISSN: 0250-7005

=> s l5 and (interleukin? or IL7)

L6 8 L5 AND (INTERLEUKIN? OR IL7)

=> d l-8 u so

L6 ANSWER 1 OF 8 MEDLINE

T1 Growth inhibition of human mammary carcinoma by
liposomal

hexadecylphosphocholine: Participation of activated
macrophages in

the antitumor mechanism.

SO INTERNATIONAL JOURNAL OF CANCER, (2001
May 1) 92 (3) 426-33.

Journal code: 0042124. ISSN: 0020-7136.

L6 ANSWER 2 OF 8 MEDLINE

T1 Alkyl-lysophospholipids as anticancer agents and
enhancers of

radiation-induced apoptosis.

SO INTERNATIONAL JOURNAL OF RADIATION
ONCOLOGY, BIOLOGY, PHYSICS, (2001 Feb

1) 49 (2) 415-9. Ref: 57

Journal code: 7603616. ISSN: 0360-3016.

L6 ANSWER 3 OF 8 MEDLINE

T1 Effect of the alkyl-lysophospholipids on the
proliferation and

differentiation of Trypanosoma cruzi.

SO ACTA TROPICA, (2000 Mar 25) 75 (2) 219-28.

Journal code: 0370374. ISSN: 0001-706X.

L6 ANSWER 4 OF 8 MEDLINE

T1 Molecular and cellular effects of
hexadecylphosphocholine

(Mitterfine) in human myeloid leukaemic cell lines.

SO EUROPEAN JOURNAL OF CANCER, (1994) 30A

(14) 2143-50.

Journal code: 9005373. ISSN: 0959-8049.

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003

ACS

TI Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2

L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003

ACS

TI Morphological changes and cytokine gene expression in tumor xenografts following treatment with the alkylphosphocholines hexadecylphosphocholine and perfosine
SO Drugs of Today (1998), 34(Suppl. F), 15-26
CODEN: MDACAP, ISSN: 0925-7656

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003

ACS

TI Influence of hexadecylphosphocholine (miltefosine) on cytokine synthesis and biological responses
SO Advances in Experimental Medicine and Biology (1996), 416(Platelet-Activating Factor and Related Lipid Mediators 2), 181-187
CODEN: AEMBAP, ISSN: 0065-2598

L6 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003

ACS

TI Maleic anhydride copolymers as antidotes for the cytotoxicity of neoplasia inhibitors
SO Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW

=> d 5 ab

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003

ACS

AB The present invention relates to a combination product comprising at least one nucleic acid contg. a sequence encoding a polypeptide or interest and at least one phospholipid of interest, for use which is simultaneous, consecutive or spread out over time, characterized in that said polypeptide and phospholipid of interest have cytotoxic activity.

=> d 5

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003

ACS

AN 2001-923645 CAPLUS
DN 13648434
TI Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal
IN Meyer, Olivier
PA Transgene S.A., Fr.
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION
NO. DATE
PI WO 2001095946 A2 20011220 WO 2001-1B1287 20010613
WO 2001095946 A3 20020906
W: AU, CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR
EP 1289568 A2 20030312 EP 2001-947745 20010613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR
US 2002025941 A1 20020228 US 2001-880038 20010614
PRAI FR 2000-7604 A 20000614
US 2000-246090P P 20001107
WO 2001-1B1287 W 20010613
OS MARPAT 13648434

=> FIL STNGUIDE
COST IN U.S. DOLLARS SINCE FILE
TOTAL ENTRY SESSION
FULL ESTIMATED COST 28.43
28.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE -0.65
0.65

FILE 'STNGUIDE' ENTERED AT 15:57:09 ON 16 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 11, 2003 (20030711/UP).

=> d 16 ab

YOU HAVE REQUESTED DATA FROM FILE 'MEDLINE, CAPLUS' - CONTINUE? (Y/N)y

L6 ANSWER 1 OF 8 MEDLINE

AB This study was undertaken to investigate the antitumor effect of liposomal hexadecylphosphocholine (L-HPC), a synthetic phospholipid encapsulated into multilamellar vesicles (MLV). The effect of these liposomes was tested in an orthotopic nude mouse model using the human mammary carcinomas MDA-MB 435 and 231. The main interest of the investigation was to study whether activated macrophages are substantially involved in the tumor growth inhibition mechanism. The growth of both MDA-MB 435 and 231 tumors in the mammary fat pad was significantly inhibited by a 14-day intraperitoneal therapy with L-HPC. The remaining tumors were shown to be heavily infiltrated with macrophages. In vitro studies of mPEM demonstrated a significant induction of macrophage-mediated tumor cytotoxicity (MMCTX) against the 2 cell lines by L-HPC. The L-HPC-mediated activation mechanism was characterized to be IL-6 and TNFalpha dependent but rather independent of IL-1alpha and nitric oxide (NO). NMA, a specific inhibitor of NO production, did not inhibit L-HPC-induced MMCTX. Furthermore, L-HPC was shown to upregulate the matrix metalloproteinases MMP-9 and MMP-2 secretion into the supernatant. Considering cytokine release and production of collagenases, the L-HPC-induced macrophage activation cascade is assumed to be comparable with that of classical activators such as lipopolysaccharide (LPS) and interferon (IFN) gamma.

As far as NO production is considered, the L-HPC activation mechanism differs from that caused by LPS and IFN gamma. Copyright 2001 Wiley-Liss, Inc.

=> d 16 4-8 ab

YOU HAVE REQUESTED DATA FROM FILE 'MEDLINE, CAPLUS' - CONTINUE? (Y/N)y

L6 ANSWER 4 OF 8 MEDLINE

AB The molecular and cellular effects of the anti-neoplastic alkylphospholipid hexadecylphosphocholine (Miltefosine, MIL) on parameters associated with growth and differentiation of human myeloid leukaemic cell lines U937, KG1 and KG1a were investigated. On a cellular level, MIL has dose-dependent differentiation-inducing growth-promoting and cytotoxic activities exemplified by induction of respiratory burst activity, stimulation of interleukin-3 (IL-3)/granulocyte-macrophage colony stimulating factor (GM-CSF)-dependent growth of the KG1 cell line in soft agar culture, inhibition of cellular net growth and finally cell death. By northern blot analysis, transcription of functional receptors for IL-3, GM-CSF, G-CSF and FcRI were studied. It was shown that MIL has stimulatory activity on IL-3 and GM-CSF receptor gene transcription. In addition, the transcription of proliferation- and differentiation-associated proteins, namely histone subtypes, c-myc and NF-kappa B p50, were studied. MIL suppressed c-myc and enhanced NF-kappa B p50 transcription in the U937 cell line, comparable to the well-characterised differentiation-inducing phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA). We conclude that the interaction of MIL with its molecular target(s) in myeloid cells induces molecular and cellular effects associated with induction of differentiation, distinct from its cytotoxic activity.

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003

ACS

AB The present invention relates to a combination product comprising at least one nucleic acid contg. a sequence encoding a polypeptide or interest and at least one phospholipid of interest, for use which is simultaneous, consecutive or spread out over time, characterized in that said polypeptide and phospholipid of interest have cytotoxic activity.

L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003

ACS

AB Hexadecylphosphocholine (HPC) is active against exptl. and clin. breast cancer in vivo, however the mechanisms of its action are unclear. The aims of this study were to further investigate the role of immunomodulation in the antitumor activity of HPC and to study the novel analog octadecyl (1,1-dimethyl-piperidino-4-yl)phosphate (D-21266, perfosine). Earlier investigations have demonstrated that redb. in tumor vol. in MT-1 human breast xenografts by HPC is accompanied by infiltration of immune cells. In this paper the earlier studies have been extended to investigate the functional activity of the infiltrating cells. MT-1 tumors transplanted s.c. to mammary fat pads of 12-wk-old NCR/nu mice were allowed to grow for approx. 22 days. HPC in 10% Tween 80/saline, or D-21266 in saline was administered orally (50 mg/kg/day) for 5 days. Ten percent Tween 80/saline alone was administered to control mice at same time. One week after the end of treatment, mice were killed and secondary immune tissues and tumors removed for histol. and reverse transcriptase-polymerase chain reaction (RT-PCR) anal. Cytokine mRNA expression was assessed by RT-PCR. mRNA for interferon- gamma, interleukin-1.beta, and tumor necrosis factor- alpha, was detected in HPC-treated tumors. These effects did not occur in control tumors or with sid. cytotoxic therapy, thus the results provide further support for the suggestion that immunomodulation may play a role in the antitumor effects of HPC. D-21266 showed similar antitumor and morphol. effects against MT-1 xenografts indicating that addnl. studies of this analog are warranted.

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003

ACS

AB In the presence of interleukin-3 or GM-CSF, miltefosine stimulated rat and mouse bone marrow cells, whereas it had no effect in the absence of interleukin-3 or GM-CSF. In addn., in rats, miltefosine decreased the suppression of granulocytes after cytotoxic treatment with cyclophosphamide, and when given for one week before the cytotoxic agent, miltefosine protected the progenitor cells. In human myeloid cell lines, miltefosine increased the interleukin-3 receptor .alpha. and .beta. c mRNA levels, but had no effect on GM-CSF receptor mRNA levels. Miltefosine also influenced the formation of TNF.alpha. in peripheral blood cells stimulated with Con A or LPS and had variable effects when given alone. Miltefosine did not affect the basal level of mRNA for TNF.alpha. or GM-CSF when given alone, but caused a prolongation of the increase in both mRNA species in response to Con A. Thus, miltefosine has a growth stimulatory effect on bone marrow cells, possibly by increasing expression of cytokine receptors. This activity may be useful in conjunction with myelosuppressive chemotherapy.

L6 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003

ACS

AB Half-amide:half-imide copolymers comprising ethylene and maleic anhydride moieties (structure given), specifically carbeximer (I; a/b = 1:2-5), decrease the cytotoxic side effects of neoplasia inhibitors. Mice treated i.v. with 21 mg adriamycin/kg died within 5 days. When 1700 mg I/kg was administered concomitantly, no lethality was shown for >30 days.

=> fil medline biosis caphus cancerlit embase
COST IN U.S. DOLLARS SINCE FILE
TOTAL

| | ENTRY | SESSION |
|---------------------|-------|---------|
| FULL ESTIMATED COST | | 0.42 |
| 37.17 | | |

| | ENTRY | SESSION |
|--|-------|---------|
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL | | |
| 3.25 | | |

| | ENTRY | SESSION |
|---------------------|-------|---------|
| CA SUBSCRIBER PRICE | | 0.00 |
| 3.25 | | |

FILE 'MEDLINE' ENTERED AT 16:09:27 ON 16 JUL 2003

FILE 'BIOSIS' ENTERED AT 16:09:27 ON 16 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS
INC.(R)

FILE 'CAPLUS' ENTERED AT 16:09:27 ON 16 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN
CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL
SOCIETY (ACS)

FILE 'CANCERLIT' ENTERED AT 16:09:27 ON 16 JUL 2003

FILE 'EMBASE' ENTERED AT 16:09:27 ON 16 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights
reserved

=> s hexadecylphosphocholine or miltefosine
L7 1680 HEXADECYLPHOSPHOCHOLINE OR
MILTEFOSINE

=> s l7 and (interleukin-2 or il-2)
L8 39 L7 AND (INTERLEUKIN-2 OR IL-2)

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9 21 DUP REM L8 (18 DUPLICATES
REMOVED)

=> d 1-21 ti so

L9 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Incensole and furanogermaenes and compounds in
treatment for inhibiting
neoplastic lesions and microorganisms
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2

L9 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Methods and compositions for enhancing
pharmaceutical treatments
SO U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S.
Ser. No. 684,293.
CODEN: USXXCO

L9 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Therapeutic modulation of the tumor inflammatory
response
SO U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO

L9 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Combination product intended for carrying out a
cytotoxic treatment, in
particular an antitumour treatment, in a mammal
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2

L9 ANSWER 5 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI Cutaneous lymphomas
SO Current Problems in Dermatology, (2000) 12/1 (25-
29).
Refs: 25
ISSN: 1040-0486 CODEN: APDEBX

L9 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Use of neomycin for treating angiogenesis-related
diseases
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2

L9 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Antioxidant enhancement of therapy for
hyperproliferative conditions
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2

L9 ANSWER 8 OF 21 MEDLINE
DUPLICATE 1
TI Induction of apoptosis in human mitogen-activated
peripheral blood
T-lymphocytes by the ether phospholipid ET-18-OC13:
involvement of the Fas
receptor/ligand system.
SO BRITISH JOURNAL OF PHARMACOLOGY, (1999
Jun) 127 (4) 813-25.
Journal code: 7502536. ISSN: 0007-1188.

L9 ANSWER 9 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI Clinical pharmacology of anticancer agents in relation
to formulations and
administration routes.
SO Cancer Treatment Reviews, (1999) 25/2 (83-101).
Refs: 221
ISSN: 0305-7372 CODEN: CTREDJ

L9 ANSWER 10 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI Inhibitors of signal transduction: The
alkylphosphocholines.
SO Drug News and Perspectives, (1999) 12/2 (69-72).
Refs: 38
ISSN: 0214-0934 CODEN: DNPEED

L9 ANSWER 11 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI Cutaneous lymphomas
SO Current Problems in Dermatology, (1997) 9/5 (137-
204).
Refs: 478
ISSN: 1040-0486 CODEN: APDEBX

L9 ANSWER 12 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI [A rational approach to the therapy of cutaneous T-cell
lymphomas].
EIN RATIONALER ANSATZ ZUR THERAPIE
KUTANER T-ZELL-LYMPHOME.
SO Onkologie, (1996) 19/3 (226-230).
ISSN: 0378-584X CODEN: ONKOD2

L9 ANSWER 13 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI Therapeutic approaches in cutaneous lymphoma.
SO Dermatologic Clinica, (1994) 12/2 (433-441).
ISSN: 0733-8635 CODEN: DRMCDD

L9 ANSWER 14 OF 21 MEDLINE
DUPLICATE 2
TI The amido black assay: a simple and quantitative
multipurpose test of
adhesion, proliferation, and cytotoxicity in microplate
cultures of
keratinocytes (HaCaT) and other cell types growing
adherently or in
suspension.
SO JOURNAL OF IMMUNOLOGICAL METHODS,
(1994 Jan 3) 167 (1-2) 1-13.
Journal code: 1305440. ISSN: 0022-1759.

L9 ANSWER 15 OF 21 BIOSIS COPYRIGHT 2003
BIOLOGICAL ABSTRACTS INC.
TI Characteristics of the inhibition of human
promyelocytic leukaemia HL60
cell growth by S-D-lactoylglutathione in vitro.
SO Leukemia Research, (1993) Vol. 17, No. 4, pp. 305-
310.
ISSN: 0145-2126.

L9 ANSWER 16 OF 21 MEDLINE
DUPLICATE 3
TI In vivo characterization of immunogenicity of a
mitoxantrone-resistant
murine P388 leukemia.
SO IN VIVO, (1993 Jan-Feb) 7 (1) 73-9.
Journal code: 8806809. ISSN: 0258-851X.

L9 ANSWER 17 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI [New treatment modalities for neoplastic skin
diseases].
NEUE BEHANDLUNGSMETHODEN BEI
HAUTTUMOREN.
SO Schweizerische Rundschau für Medizin/Praxis, (1992)
81/19 (610-614).
ISSN: 0369-8394 CODEN: SRMPDJ

L9 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Immunomodulatory activity of
hexadecylphosphocholine:
hexadecylphosphocholine-mediated enhancement of T-
cell response
SO Cytokines Hemopoiesis, Oncol., AIDS II (1992), 389-
95.
Editor(s): Freud.
Mathias. Publisher: Springer, Berlin, Germany.
CODEN: 59UJAP

L9 ANSWER 19 OF 21 BIOSIS COPYRIGHT 2003
BIOLOGICAL ABSTRACTS INC.
TI HEXADECYLPHOSPHOCHOLINE INDUCES
CYTOKINE EXPRESSION IN HUMAN
MONONUCLEAR CELLS.
SO 83RD ANNUAL MEETING OF THE AMERICAN
ASSOCIATION FOR CANCER RESEARCH, SAN
DIEGO, CALIFORNIA, USA, MAY 20-23, 1992.
PROC AM ASSOC CANCER RES ANNU
MEET. (1992) 33 (0), 300.
CODEN: PAMREA.

L9 ANSWER 20 OF 21 MEDLINE
DUPLICATE 4
TI Hexadecylphosphocholine induces interferon-gamma
secretion and
expression of GM-CSF mRNA in human mononuclear
cells.
SO CELLULAR IMMUNOLOGY, (1992 Apr 15) 141 (1)
161-8.

Journal code: 1246405. ISSN: 0008-8749.

L9 ANSWER 21 OF 21 MEDLINE
DUPLICATE 5
TI Hexadecylphosphocholine-mediated enhancement of
T-cell responses
to interleukin 2.
SO CELLULAR IMMUNOLOGY, (1991 Oct 1) 137 (1)
232-8.
Journal code: 1246405. ISSN: 0008-8749.

=> d 21

L9 ANSWER 21 OF 21 MEDLINE
DUPLICATE 5
AN 91356566 MEDLINE
DN 91356566 PubMed ID: 1909215
TI Hexadecylphosphocholine-mediated enhancement of
T-cell responses
to interleukin 2.
AU Vehmeyer K; Scheurich P; Eibl H; Unger C
CS Department of Internal Medicine, University of
Göttingen, Federal Republic
of Germany.
SO CELLULAR IMMUNOLOGY, (1991 Oct 1) 137 (1)
232-8.
Journal code: 1246405. ISSN: 0008-8749.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199110
ED Entered STN: 19911027
Last Updated on STN: 19911027
Entered Medline: 19911004

=> d 21 ab

L9 ANSWER 21 OF 21 MEDLINE
DUPLICATE 5
AB The effect of low-dose hexadecylphosphocholine (He-
PC) on normal
peripheral mononuclear cells (PMNC) was studied.
Interferon-gamma (IFN-g)
production, interleukin 2 (IL-2)
receptor, and HLA-DR antigen expression were
investigated, representing
typical T-cell activation parameters. In PMNC cultures,
He-PC
dose-dependently enhanced the production of IFN-g,
provided IL-
2 had been added exogenously. Without IL-2
He-PC was ineffective. In some cultures, at a
concentration of 8
micrograms/ml He-PC stimulated the secretion of IFN-g
more than 20-fold
compared to untreated controls. Although He-PC by
itself lacked mitogenic
activity, this compound also stimulated IFN-g
production in the presence
of suboptimal doses of phytohemagglutinin (PHA).
Immunofluorescence
studies demonstrated that He-PC also increased IL-2
receptor and HLA-DR antigen expression under these
experimental
conditions. Taken together, these results indicate that
He-PC may possess
immunomodulatory activity also in vivo, acting as a
costimulator for the
IL-2-mediated T-cell activation process.

=> d 21 au ti so

L9 ANSWER 21 OF 21 MEDLINE
DUPLICATE 5
AU Vehmeyer K; Scheurich P; Eibl H; Unger C
TI Hexadecylphosphocholine-mediated enhancement of
T-cell responses
to interleukin 2.
SO CELLULAR IMMUNOLOGY, (1991 Oct 1) 137 (1)
232-8.
Journal code: 1246405. ISSN: 0008-8749.

=>
Connection closed by remote host

=> fil medline biosis cancerlit caplus embase
COST IN U.S. DOLLARS SINCE FILE
TOTAL

ENTRY SESSION
FULL ESTIMATED COST 0.21

FILE 'MEDLINE' ENTERED AT 16:48:12 ON 16 JUL 2003

FILE 'BIOSIS' ENTERED AT 16:48:12 ON 16 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS
INC.(R)

FILE 'CANCERLIT' ENTERED AT 16:48:12 ON 16 JUL 2003

FILE 'CAPLUS' ENTERED AT 16:48:12 ON 16 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN
CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL
SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 16:48:12 ON 16 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights
reserved.

=> s hexadecylphosphocholine or miltefosine
L1 1680 HEXADECYLPHOSPHOCHOLINE OR
MILTEFOSINE

=> s il1 and (il-2 or interleukin-2)
L2 39 IL1 AND (IL-2 OR INTERLEUKIN-2)

=> dup rem 12
PROCESSING COMPLETED FOR L2
L3 21 DUP REM L2 (18 DUPLICATES
REMOVED)

=> d 1-11 ti so

L3 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Incensole and furanogermacrenes and compounds in
treatment for inhibiting
neoplastic lesions and microorganisms
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2

L3 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Methods and compositions for enhancing
pharmaceutical treatments
SO U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S.
Ser. No. 684,293.
CODEN: USXXCO

L3 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Therapeutic modulation of the tumor inflammatory
response
SO U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO

L3 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Combination product intended for carrying out a
cytotoxic treatment, in
particular an antitumor treatment, in a mammal
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2

L3 ANSWER 5 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI Cutaneous lymphomas.
SO Current Problems in Dermatology, (2000) 12/1 (25-
29).
Refs: 25
ISSN: 1040-0486 CODEN: APDEBX

L3 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Use of neomycin for treating angiogenesis-related
diseases
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2

L3 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2003
ACS
TI Antioxidant enhancement of therapy for
hyperproliferative conditions
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2

L3 ANSWER 8 OF 21 MEDLINE
DUPLICATE 1
TI Induction of apoptosis in human mitogen-activated
peripheral blood
T-lymphocytes by the ether phospholipid ET-18-OCH3:
involvement of the Fas
receptor/ligand system.
SO BRITISH JOURNAL OF PHARMACOLOGY, (1999
Jun) 127 (4) 813-25.
Journal code: 7502536. ISSN: 0007-1188.

L3 ANSWER 9 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI Clinical pharmacology of anticancer agents in relation
to formulations and
administration routes.

SO Cancer Treatment Reviews, (1999) 25/2 (83-101).
Refs: 221
ISSN: 0305-7372 CODEN: CTREDJ

L3 ANSWER 10 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI Inhibitors of signal transduction: The
alkylphosphocholines.
SO Drug News and Perspectives, (1999) 12/2 (69-72).
Refs: 38
ISSN: 0214-0934 CODEN: DNPEED

L3 ANSWER 11 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI Cutaneous lymphomas.
SO Current Problems in Dermatology, (1997) 9/5 (137-
204).
Refs: 478
ISSN: 1040-0486 CODEN: APDEBX

=> d 9 ab

L3 ANSWER 9 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
AB In the past years, alternative administration routes and
pharmaceutical
formulations of anticancer agents have been investigated
in order to
improve conventional chemotherapy treatment. The
impact of these
adjustments on the pharmacokinetics and
pharmacodynamics is discussed. A
review of the literature shows many examples of
alternative administration
forms of anticancer agents with improved
pharmacokinetics. Local
administration routes have been investigated in order to
reduce the
systemic toxicity and to enhance the local efficacy of
conventional
chemotherapy. Oral administration of anticancer agents
is preferred by
patients for its convenience and its potential for
outpatient treatment.
In addition, oral administration facilitates a prolonged
exposure to the
cytotoxic agent. However, poor bioavailability and
substantial
interpatient variability are noted as limitations for oral
chemotherapy.
increased tumour selectivity can also be achieved by the
use of specific
pharmaceutical formulations, such as liposomes and
macromolecular drug
conjugates. The composition of these formulations often
determine the
pharmacokinetic behaviour of the formulated drug. In
conclusion, several
alternative administration forms of anticancer agents
have been designed
in the past years, with the potential for improvement of
conventional
chemotherapy; however, more extensive clinical
evaluation of these novel
strategies is warranted to prove their real clinical value.

=> d 9 kwic

L3 ANSWER 9 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.

CT Medical Descriptors:
drug . . .
DT, drug therapy
cyclophosphamide: PK, pharmacokinetics
bisacetatoamminedichlorocyclohexylamineplatinum:
AD, drug administration
bisacetatoamminedichlorocyclohexylamineplatinum:
DT, drug therapy
bisacetatoamminedichlorocyclohexylamineplatinum:
PK, pharmacokinetics
trofosfamide: AD, drug administration
trofosfamide: DT, drug therapy
trofosfamide: PK, pharmacokinetics
miltefosine: AD, drug administration
miltefosine: DT, drug therapy
miltefosine: PK, pharmacokinetics
hurtlecan: AD, drug administration
hurtlecan: DT, drug therapy
hurtlecan: PK, pharmacokinetics
doxiluridine: AD, drug administration
doxiluridine: DT, drug therapy
doxiluridine: PK, pharmacokinetics
UFT: AE, adverse. . . 5' myristylphosphate: AE,
adverse drug reaction
flozuridine 5' myristylphosphate: CT, clinical trial
flozuridine 5' myristylphosphate: AD, drug
administration
flozuridine 5' myristylphosphate: DT, drug therapy
interleukin 2: AD, drug administration
interleukin 2: DT, drug therapy
unindexed drug
RN. . . 23541-50-6; (idarubicin) 57852-57-0, 58957-92-9,
(etoposide)
33419-42-0; (teniposide) 29767-20-2; (vincristine) 57-
22-7; (vinblastine)
865-21-4; (vindesine) 53643-48-4; (cyclophosphamide)
50-18-0;
(bisacetatoamminedichlorocyclohexylamineplatinum)
129580-63-8;
(trofosfamide) 22089-22-1; (miltefosine) 58066-85-6;

(hurtlecan) 149882-10-0, 155773-58-3; (doxiluridine)
3094-09-5; (UFT)
74578-38-4; (capecitabine) 154361-50-9; (carmofur)
61422-45-5;
(flozuridine 5' myristylphosphate) 86976-77-4;
(interleukin
2) 85898-30-2

=> d 9 au ti so

L3 ANSWER 9 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
AU Meerum Terwogt J.M.; Schellens J.H.M.; Ten Bokkel
Huinkink W.W.; Beijnen
J.H.
TI Clinical pharmacology of anticancer agents in relation
to formulations and
administration routes.
SO Cancer Treatment Reviews, (1999) 25/2 (83-101).
Refs: 221
ISSN: 0305-7372 CODEN: CTREDJ

=> d 11 ab

L3 ANSWER 11 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
AB The skin is one of the organs most frequently affected
by extranodal
lymphomas. Cutaneous lymphomas are peculiar in many
aspects. (1) In
contrast to nodal lymphomas, cutaneous T-cell
lymphomas are more frequent
than B-cell lymphomas. (2) Cutaneous T-cell
lymphomas develop in a
multistep process, exhibiting distinct clinical,
histologica, and
molecular-biologic features. They progress very slowly
over a period of
years or decades. (3) The disease becomes manifest very
early on. (4) The
skin provides a unique structural and humoral
(cytokines) microenvironment
to attract T cells and B cells to home to under distinct
promotional
conditions. (5) Treatment strategies for cutaneous
lymphomas are quite
different from those for nodal lymphomas.

=> d 11 kwic

L3 ANSWER 11 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.

CT Medical Descriptors:
*skin . . .
drug combination
cyclophosphamide: DT, drug therapy
doxorubicin: CB, drug combination
doxorubicin: DT, drug therapy
vincristine: CB, drug combination
vincristine: DT, drug therapy
monoclonal antibody: DT, drug therapy
miltefosine: CT, clinical trial
miltefosine: DT, drug therapy
interleukin 2
methotrexate: DT, drug therapy
cisplatin: DT, drug therapy
etoposide: DT, drug therapy
teniposide: DT, drug therapy
fludarabine: DT, drug therapy
pentostatin: DT, drug therapy
bleomycin: DT, . . .
RN. . . (etretinate) 54350-48-0; (etretin) 55079-83-9;
(isotretinoin)
4759-48-2; (gamma interferon) 82115-62-6;
(prednisone) 53-03-2;
(chlorambucil) 305-03-3; (cyclophosphamide) 50-18-0;
(doxorubicin)
23214-92-8, 25316-40-9; (vincristine) 57-22-7;
(miltefosine)
58066-85-6; (interleukin 2) 85898-30-2; (methotrexate)
15475-56-6, 59-05-2, 7413-34-5; (cisplatin) 15663-27-1,
26035-31-4,
96081-74-2; (etoposide) 33419-42-0; (teniposide)
29767-20-2; (fludarabine)
21679-14-1; (pentostatin) 53910-25-1; (bleomycin)
11056-06-7; (vindesine).

=> d 12-21 ti so

L3 ANSWER 12 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI [A rational approach to the therapy of cutaneous T-cell
lymphomas].
EIN RATIONALER ANSATZ ZUR THERAPIE
KUTANER T-ZELL-LYMPHOME.
SO Onkologie, (1996) 19/3 (226-230).
ISSN: 0378-584X CODEN: ONKOD2

L3 ANSWER 13 OF 21 EMBASE COPYRIGHT 2003
ELSEVIER SCI. B.V.
TI Therapeutic approaches in cutaneous lymphoma.
SO Dermatologic Clinics, (1994) 12/2 (433-441).
ISSN: 0733-8635 CODEN: DRMCDJ

L3 ANSWER 14 OF 21 MEDLINE
DUPLICATE 2

TI The amido black assay: a simple and quantitative multipurpose test of adhesion, proliferation, and cytotoxicity in microplate cultures of keratinocytes (HaCaT) and other cell types growing adherently or in suspension.

SO JOURNAL OF IMMUNOLOGICAL METHODS, (1994 Jan 3) 167 (1-2) 1-13.
Journal code: 1305440. ISSN: 0022-1759.

L3 ANSWER 15 OF 21 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI Characteristics of the inhibition of human promyelocytic leukemia HL60

cell growth by S-D-lactoylglutathione in vitro.

SO Leukemia Research, (1993) Vol. 17, No. 4, pp. 305-310.
ISSN: 0145-2126.

L3 ANSWER 16 OF 21 MEDLINE
DUPLICATE 3

TI In vivo characterization of immunogenicity of a mitoxantrone-resistant murine P388 leukemia.

SO IN VIVO, (1993 Jan-Feb) 7 (1) 73-9.
Journal code: 8806809. ISSN: 0258-851X.

L3 ANSWER 17 OF 21 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

TI [New treatment modalities for neoplastic skin diseases]

NEUE BEHANDLUNGSMETHODEN BEI

HAUTTUMOREN.

SO Schweizerische Rundschau für Medizin/Praxis, (1992) 81/19 (610-614).

ISSN: 0369-8394 CODEN: SRMPDJ

L3 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2003 ACS

TI Immunomodulatory activity of

hexadecylphosphocholine:

hexadecylphosphocholine-mediated enhancement of T-cell response

SO Cytokines Hemopoiesis, Oncol., AIDS II (1992), 389-95. Editor(s): Freund, Mathias. Publisher: Springer, Berlin, Germany.
CODEN: 59UJAP

L3 ANSWER 19 OF 21 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI HEXADECYLPHOSPHOCHOLINE INDUCES CYTOKINE EXPRESSION IN HUMAN MONONUCLEAR CELLS

SO 83RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, SAN DIEGO, CALIFORNIA, USA, MAY 20-23, 1992. PROC AM ASSOC CANCER RES ANNU MEET. (1992) 33 (0), 300.
CODEN: PAMREA.

L3 ANSWER 20 OF 21 MEDLINE
DUPLICATE 4

TI Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells.

SO CELLULAR IMMUNOLOGY, (1992 Apr 15) 141 (1) 161-8.

Journal code: 1246405. ISSN: 0008-8749.

L3 ANSWER 21 OF 21 MEDLINE
DUPLICATE 5

TI Hexadecylphosphocholine-mediated enhancement of T-cell responses to interleukin 2.

SO CELLULAR IMMUNOLOGY, (1991 Oct 1) 137 (1) 232-8.

Journal code: 1246405. ISSN: 0008-8749.

=> d 16 ab

L3 ANSWER 16 OF 21 MEDLINE

DUPLICATE 3

AB The Mitoxantrone-resistant murine leukemia P388/Mitox, expressing the

multidrug-resistant phenotype, has a higher immunogenicity than the parent

sensitive P388. This could be shown in vivo by

immunization with

lethally-irradiated tumor cells. If the P388/Mitox was

used for

immunization before subsequent challenge with viable

tumor cells of the

same line, this resulted in a partial rejection of tumors

and production

of a substantial number of tumor-free survivors. For an effective

immunization at least two primings s.c., i.v. or i.p. with

at least 10(6)

irradiated cells were necessary. This protected the

recipient mice from a

challenge of up to 10(8) viable cells over a period of at

least 75 days.

Treatment of BDF1 mice with the T-cell suppressor

Cyclosporin A prevents

immunization. In nude mice no immunization effect

could be obtained. It

was possible to transfer immunity adoptively with

spleen cells from mice,

which were treated with irradiated tumor cells of the P388/Mitox line.

Treatment of tumor-bearing mice with IL-2 resulted in a prolongation of survival both when it was administered prophylactically before transplantation of P388/Mitox and at an advanced stage (day 7-11).

Also the alkyl-phosphocholine hexadecylphosphocholine was significantly effective in the resistant but not in the parent P388

leukemia. The data presented demonstrate that by development of a multidrug-resistance, concomitantly a xenogenization must have taken place

which leads to a recognition of cells by immune mechanisms. In our model,

T-lymphocytes and NK-/LAK-cells probably play a role in the

immunologically conditioned rejection of tumor cells of the P388/Mitox

leukemia.(ABSTRACT TRUNCATED AT 250

WORDS)

=> d 18 ab

L3 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2003 ACS

AB The effect of low-dose hexadecylphosphocholine (He-PC) on normal

peripheral mononuclear cells (PMNC) was studied.

Interferon-gamma

(IFN-gamma) prodn., interleukin-2 (IL-

2) receptor and HLA-DR antigen expression were

investigated,

representing typical T-cell activation parameters. In

PMNC cultures,

He-PC dose-dependently enhanced the prodn. of IFN-

gamma., provided

IL-2 had been added exogenously. Without IL-

2 He-PC was ineffective. In some cultures, at a concn.

of 8

mu g/mL He-PC stimulated the secretion of IFN-

gamma. 20-fold as compared

to untreated controls. Although He-PC by itself lacked

mitogenic

activity, this compd. stimulated IFN-gamma prodn. in

the presence of

suboptimal doses of phytohemagglutinin.

Immunofluorescence studies

demonstrated that He-PC also increased IL-2 receptor

and HLA-DR antigen expression under these exptl.

conditions. Thus, He-PC

may possess immunomodulatory activity also in vivo,

acting as a

costimulator for the IL-2-mediated T-cell activation

process.

12 ANSWER 1 OF 5 MEDLINE on STN
U Chonn A; Cullis P R
I Recent advances in liposomal drug-delivery systems.

SO CURRENT OPINION IN BIOTECHNOLOGY, (1995 Dec) 6 (6) 698-708.
Ref: 120
Journal code: 9100492. ISSN: 0958-1669.

L12 ANSWER 2 OF 5 MEDLINE on STN

AU Chonn A; Semple S C; Cullis P R

TI Beta 2-glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles.

SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1995 Oct 27) 270 (43) 25845-9.

Journal code: 2985121R. ISSN: 0021-9258.

L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

IN Wilschut, Jan C.; Scherrer, Peter; Chonn, Arcadio

TI Viro-some-mediated intracellular delivery of therapeutic agents

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

L12 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AU Chonn, Arcadio; Cullis, Pieter R.

TI Recent advances in liposomal drug-delivery systems

SO Current Opinion in Biotechnology (1995), 6(6), 698-708

CODEN: CUOBE3; ISSN: 0958-1669

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AU Chonn, Arcadio; Semple, Sean C.; Cullis, Pieter R.

TI .beta.2-glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles

SO Journal of Biological Chemistry (1995), 270(43), 25845-9

CODEN: JBCHA3; ISSN: 0021-9258

=> d 1 ab

L12 ANSWER 1 OF 5 MEDLINE on STN

AB Liposomal drug-delivery systems have come of age in recent years, with several liposomal drugs currently in advanced clinical trials or already on the market. It is clear from numerous pre-clinical and clinical studies that drugs, such as antitumor drugs, packaged in liposomes exhibit reduced toxicities, while retaining, or gaining enhanced, efficacy. This results, in part, from altered pharmacokinetics, which lead to drug accumulation at disease sites, such as tumors, and reduced distribution to sensitive tissues. Fusogenic liposomal systems that are under development have the potential to deliver drugs intracellularly, and this is expected to markedly enhance therapeutic activity. Advances in liposome design are leading to new applications for the delivery of new biotechnology products, such as recombinant proteins, antisense oligonucleotides and cloned genes.

=> s Chonn-A7/au and liposom?

L13 37 CHONN-A7/AU AND LIPOSOM?

=> dup rem 113

PROCESSING COMPLETED FOR L13

L14 24 DUP REM L13 (13 DUPLICATES REMOVED)

=> s 114 and review/dt

L15 5 L14 AND REVIEW/DT

=> d 1-5 au ti so

L15 ANSWER 1 OF 5 MEDLINE on STN

AU Chonn A; Cullis P R

TI Recent advances in liposomal drug-delivery systems.

SO CURRENT OPINION IN BIOTECHNOLOGY, (1995 Dec) 6 (6) 698-708.

Ref: 120

Journal code: 9100492. ISSN: 0958-1669.

L15 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AU Semple, Sean C.; Chonn, Arcadio; Cullis, Pieter R.

TI Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behavior in vivo

SO Advanced Drug Delivery Reviews (1998), 32(1,2), 3-17

CODEN: ADDREP; ISSN: 0169-409X

L15 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AU Chonn, Arcadio; Cullis, Pieter R.

TI Recent advances in liposome technologies and their applications for systemic gene delivery

SO Advanced Drug Delivery Reviews (1998), 30(1-3), 73-83

CODEN: ADDREP; ISSN: 0169-409X

L15 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AU Semple, Sean C.; Chonn, Arcadio

TI Liposome-blood protein interactions in relation to liposome clearance

SO Journal of Liposome Research (1996), 6(1), 33-60

CODEN: JLREE7; ISSN: 0898-2104

L15 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AU Chonn, Arcadio; Cullis, Pieter R.

TI Ganglioside GM1 and hydrophilic polymers increase liposome

circulation times by inhibiting the association of blood proteins

SO Journal of Liposome Research (1992), 2(3), 397-410

CODEN: JLREE7; ISSN: 0898-2104

=> d 3 ab

L15 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AB A review with 104 refs. The recent clin. successes experienced by liposomal drug delivery systems stem from the ability to produce well-defined liposomes that can be composed of a wide variety of lipids, have high drug-trapping efficiencies and have a narrow size distribution, averaging less than 100 nm in diam. Agents that prolong the circulation lifetime of liposomes, enhance the delivery of liposomal drugs to specific target cells, or enhance the ability of liposomes to deliver drugs intracellularly can be incorporated to further increase the therapeutic activity. The phys. and chem. requirements for optimum liposome drug delivery systems will likely apply to lipid-based gene delivery systems. As a result, the development of liposomal delivery systems for systemic gene delivery should follow similar strategies.

=> d 3 au ti so ab

L15 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

AU Chonn, Arcadio; Cullis, Pieter R.

TI Recent advances in liposome technologies and their applications for systemic gene delivery

SO Advanced Drug Delivery Reviews (1998), 30(1-3), 73-83

CODEN: ADDREP; ISSN: 0169-409X

AB A review with 104 refs. The recent clin. successes experienced by liposomal drug delivery systems stem from the ability to produce well-defined liposomes that can be composed of a wide variety of lipids, have high drug-trapping efficiencies and have a narrow size distribution, averaging less than 100 nm in diam. Agents that prolong the circulation lifetime of liposomes, enhance the delivery of liposomal drugs to specific target cells, or enhance the ability of liposomes to deliver drugs intracellularly can be incorporated to further increase the therapeutic activity. The phys. and chem. requirements for optimum liposome drug delivery systems will likely apply to lipid-based gene delivery systems. As a result, the development of liposomal delivery systems for systemic gene delivery should follow similar strategies.

=> s DOPE (S) adjuvant

L16 8 DOPE (S) ADJUVANT

=> dup rem 116

PROCESSING COMPLETED FOR L16

L17 8 DUP REM L16 (0 DUPLICATES REMOVED)

=> d 1-8 au ti so

L17 ANSWER 1 OF 8 CANCERLIT on STN

AU D'Souza S; Rosseels V; Denis O; Tanghe A; De Smet N; Jurion F; Palfliet K;

Castiglioni N; Vanonckelen A; Wheeler C; Huygen K

TI Improved tuberculosis DNA vaccines by formulation in cationic lipids.

SO INFECTION AND IMMUNITY, (2002 Jul) 70 (7) 3681-8.

Journal code: 0246127. ISSN: 0019-9567.

L17 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN

IN Meyer, Olivier

TI Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

L17 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN

IN Ellis, John Albert; Allan, Gordon Moore; Meehan, Brian; Clark, Edward; Haines, Deborah; Hassard, Lori; Harding, John; Charreyre, Catherine

Elisabeth; Chappuis, Gilles Emile; Krakowka, George Steve; Audonnet,

Jean-Christophe Francis; McNeilly, Francis

TI Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2

SO PCT Int. Appl., 133 pp.

CODEN: PIXXD2

L17 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN

IN Hermanson, Gary George

TI cDNAs encoding the Flt-3 receptor ligand and there use as adjuvants in vector vaccines

SO PCT Int. Appl., 148 pp.

CODEN: PIXXD2

L17 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN

IN Audonnet, Jean-Christophe Francis; Baudu, Philippe Guy Nicolas; Brunet, Sylvie Claudine

TI Feline calicivirus genes and vaccines, in particular recombined vaccines

SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2

L17 ANSWER 6 OF 8 CANCERLIT on STN
AU Guy B; Pascal N; Francon A; Bonnin A; Gimenez S; Lafay-Vialon E; Trannoy E; Haensler J
TI Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine.
SO VACCINE, (2001 Feb 8) 19 (13-14) 1794-805.
Journal code: 8406899. ISSN: 0264-410X.

L17 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
IN Wheeler, Carl J.
TI Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

L17 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AU Norman, Jon; Hartikka, Jukka; Strauch, Pamela; Manthorpe, Marston
TI Adjuvants for plasmid DNA vaccines
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

=> s DOPE and adjuvant and review/dt
L18 1 DOPE AND ADJUVANT AND REVIEW/DT
=> d

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:679109 CAPLUS
DN 132:164839
TI Adjuvants for plasmid DNA vaccines
AU Norman, Jon; Hartikka, Jukka; Strauch, Pamela; Manthorpe, Marston
CS Vical Inc., San Diego, CA, USA
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN
PB Humana Press Inc.
DT Journal; General Review
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 1 ab

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
AB A review with 38 refs. discussing the effects of the co-injection of bupivacaine (BP), polyvinyl pyrrolidone (PVP), or DMRIE:DOPE cationic liposomes on plasmid DNA-mediated luciferase gene expression and antibody responses to influenza nucleoprotein (NP) antigen.

=> s DOPE and adjuvant
L19 28 DOPE AND ADJUVANT
=> dup rem l19
PROCESSING COMPLETED FOR L19
L20 24 DUP REM L19 (4 DUPLICATES REMOVED)
=> d 15-24 ti so

L20 ANSWER 15 OF 24 MEDLINE on STN DUPLICATE 2
TI Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine.
SO VACCINE, (2001 Feb 8) 19 (13-14) 1794-805.
Journal code: 8406899. ISSN: 0264-410X.

L20 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI In vivo immune responses induced by CpG oligonucleotides encapsulated in sterically stabilized cationic liposomes
SO Proceedings - 28th International Symposium on Controlled Release of Bioactive Materials and 4th Consumer & Diversified Products Conference, San Diego, CA, United States, June 23-27, 2001 (2001), Volume 2, 1057-1058
Publisher: Controlled Release Society, Minneapolis, Minn.
CODEN: 69CNY8

L20 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Porcine circovirus vaccine
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

L20 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

L20 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Method for transferring an gene of interest into a cell by using C1 complement factor subunit and uses thereof in gene therapy
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW

L20 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Adjuvants for plasmid DNA vaccines
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

L20 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Transfecting compositions comprising DNA-binding, disulfide bond-containing compounds and their use in gene therapy
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2

L20 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes
SO Vaccine (1999), 17(11-12), 1540-1548
CODEN: VACCDE; ISSN: 0264-410X

L20 ANSWER 23 OF 24 MEDLINE on STN
TI Transfection of cultured myoblasts in high serum concentration with DODAC:DOPE liposomes.
SO GENE THERAPY, (1998 Oct) 5 (10) 1306-13.
Journal code: 9421525. ISSN: 0969-7128.

L20 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2003 ACS on STN
TI Protamine sulfate enhances lipid-mediated gene transfer
SO Gene Therapy (1997), 4(9), 961-968
CODEN: GETHEC; ISSN: 0969-7128

=> d 23 ab

L20 ANSWER 23 OF 24 MEDLINE on STN
AB The inhibitory effect of serum is one of the main obstacles to the in vivo use of cationic liposomes as a DNA delivery system. We have found that a novel liposome formulation, DODAC:DOPE (1:1) is totally resistant to the inhibitory effects of serum for transfection of cultured myoblasts and myotubes. Transfection with a lacZ reporter gene in the presence of 95% fetal bovine serum gave up to 25% beta-gal-positive cells in C2C12 myoblasts and about six-fold less in primary human myoblasts. The lower transgene expression in primary cells does not appear to be a result of less DNA uptake but might result from differences in intracellular trafficking of the complexes. DODAC-based liposomes are unique in their resistance to serum inhibition and may therefore be valuable for the systemic delivery of genetic information to muscle and other tissues.

=> s (dioleoylphosphatidylethanolamine or DOPE) and adjuvant
L21 33 (DIOLEOYLPHOSPHATIDYLETHANOLAMINE OR DOPE) AND ADJUVANT
=> dup rem l21
PROCESSING COMPLETED FOR L21
L22 29 DUP REM L21 (4 DUPLICATES REMOVED)
=> d 15-29 ti so

L22 ANSWER 15 OF 29 MEDLINE on STN DUPLICATE 2
TI Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine.
SO VACCINE, (2001 Feb 8) 19 (13-14) 1794-805.
Journal code: 8406899. ISSN: 0264-410X.

L22 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI In vivo immune responses induced by CpG oligonucleotides encapsulated in sterically stabilized cationic liposomes
SO Proceedings - 28th International Symposium on Controlled Release of Bioactive Materials and 4th Consumer & Diversified Products Conference, San Diego, CA, United States, June 23-27, 2001 (2001), Volume 2, 1057-1058
Publisher: Controlled Release Society, Minneapolis, Minn.
CODEN: 69CNY8

L22 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Surface-Linked Liposomal Antigen Induces IgE-Selective Unresponsiveness Regardless of the Lipid Components of Liposomes
SO Bioconjugate Chemistry (2001), 12(3), 391-395
CODEN: BCCHES; ISSN: 1043-1802

L22 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Porcine circovirus vaccine
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

L22 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

L22 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Method for transferring an gene of interest into a cell by using C1
complement factor subunit and uses thereof in gene therapy
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW

L22 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Activation of host antitumoral responses by cationic lipid/DNA complexes
SO Cancer Gene Therapy (2000), 7(3), 353-359
CODEN: CGTHEG; ISSN: 0929-1903

L22 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Adjuvants for plasmid DNA vaccines
SO Methods in Molecular Medicine (2000), 29, 185-196
CODEN: MMMEFN

L22 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Transfecting compositions comprising DNA-binding, disulfide
bond-containing compounds and their use in gene therapy
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2

L22 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted
pH-sensitive liposomes
SO Vaccine (1999), 17(11-12), 1540-1548
CODEN: VACCDE; ISSN: 0264-410X

L22 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Methods for in vivo gene transfer into bladder without viral vectors
SO Osaka-shi Igakkai Zasshi (1999), 48(3-4), 435-442
CODEN: OIGZDE; ISSN: 0386-4103

L22 ANSWER 26 OF 29 MEDLINE on STN
TI Transfection of cultured myoblasts in high serum concentration with
DODAC:
DOPE liposomes.
SO GENE THERAPY, (1998 Oct) 5 (10) 1306-13.
Journal code: 9421525. ISSN: 0969-7128.

L22 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Novel adjuvant compositions and vaccine formulations comprising
same
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2

L22 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
TI Protamine sulfate enhances lipid-mediated gene transfer
SO Gene Therapy (1997), 4(9), 961-968
CODEN: GETHEC; ISSN: 0969-7128

L22 ANSWER 29 OF 29 CANCERLIT on STN
TI PH-SENSITIVE LIPOSOMES FOR THE DELIVERY OF
IMMUNOMODULATORS.
SO UCLA Symp Mol Cell Biol, (1989) New Ser 89 427-39.

=> d 27 ab

L22 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
AB An adjuvant for administration to a host animal to enhance
immune response, comprising a polysaccharide-phospholipid conjugate, whose
polysaccharide moiety may for example comprise a modified glucan,
chitosan, or alginate polysaccharide, conjugated to a phospholipid. The
adjuvant may be suitably formulated with an antigen to provide a
therapeutic vaccine for a variety of disease states and/or physiol.
conditions.

=> d 27

L22 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:181130 CAPLUS
DN 126:176905

TI Novel adjuvant compositions and vaccine formulations comprising
same

IN Parikh, Indu

PA Research Triangle Pharmaceuticals, USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

| | | | | | |
|----|------------|----|----------|-----------------|----------|
| PI | WO 9701330 | A1 | 19970116 | WO 1996-US11051 | 19960626 |
|----|------------|----|----------|-----------------|----------|

W: AU, CA, JP, KR

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,

SE

| | | | | | |
|----|---------|----|----------|-----------------|----------|
| CA | 2219904 | AA | 19970116 | CA 1996-2219904 | 19960626 |
|----|---------|----|----------|-----------------|----------|

| | | | | | |
|----|---------|----|----------|---------------|----------|
| AU | 9664007 | A1 | 19970130 | AU 1996-64007 | 19960626 |
|----|---------|----|----------|---------------|----------|

| | | | | | |
|----|--------|----|----------|----------------|----------|
| EP | 857059 | A1 | 19980812 | EP 1996-923519 | 19960626 |
|----|--------|----|----------|----------------|----------|

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
JP 2001523216 T2 20011120 JP 1997-504586, 19960626
PRAI US 1995-464969 A 19950626
WO 1996-US11051 W 19960626